Cipla slumps nearly 8% after USFDA warning letter for manufacturing lapses
After an inspection at the Pithampur plant, the USFDA issued a warning letter stating that the company's methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to good manufacturing practices, and that its drug products are adulterated.
Source: indiatimes.com